CD274 and neoplasm: The data from KEYNOTE-189 and KEYNOTE-407 studies showed that PD-L1 ≥ 50% was still associated with greater benefits with pembrolizumab-chemotherapy combination, but its predictive value was reduced as the survival benefits were significant across all PD-L1 tumor proportion score (TPS) groups, including patients with TPS < 1% [7].